| Literature DB >> 35281886 |
Siyu Guo1, Yingying Tan1, Zhihong Huang1, Yikui Li2, Weiyu Liu2, Xiaotian Fan1, Jingyuan Zhang1, Antony Stalin3, Changgeng Fu2, Zhishan Wu1, Penglong Wang1, Wei Zhou1,4, Xinkui Liu1, Chao Wu1, Shanshan Jia1, Jinyan Zhang2, Xiaoxia Duan5, Jiarui Wu1.
Abstract
Introduction: Danhong injection (DHI) is a traditional Chinese medicine preparation commonly used in the clinical treatment of acute myocardial infarction (AMI). In this study, the active components of DHI and its mechanism in the treatment of AMI were investigated.Entities:
Keywords: Danhong injection; acute myocardial infarction; experiment validation; molecular docking; systems pharmacology
Year: 2022 PMID: 35281886 PMCID: PMC8905633 DOI: 10.3389/fphar.2022.839936
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
FIGURE 1Workflow diagram of this study.
FIGURE 2The UPLC-QE-Orbitrap-MS chromatography of standard substances (A) and DHI (B). (C) 2D structure diagram of key compounds.
FIGURE 3Compound-target network of DHI and Compound-AMI target network. (A) Compound-target network of DHI. The red represents the main compound of DHI, and the green represents the corresponding target of the compound. (B) Venn diagram of DHI targets and AMI targets. (C) Compound-AMI target network. The green represents the main compound of DHI, and the blue represents the common target of compound and AMI.
FIGURE 4Protein-protein interaction network and module analysis. (A) DHI-AMI target protein-protein interaction network. (B) Module 1. (C) Module 2. (D) Module 3. The purple represents the common target of DHI and AMI, and the red represents the top 10 targets. (E) The interconnection diagram of 10 key targets. From yellow to red, the darker the color, the higher the MCC score.
FIGURE 5GO and KEGG pathway enrichment analysis. (A) Go enrichment analysis of protein-protein interaction targets. (B) KEGG pathway enrichment analysis of protein-protein interaction targets. (C) Go enrichment analysis of module 1. (D) KEGG pathway enrichment analysis of module 1. (E) Go enrichment analysis of module 2. (F) KEGG pathway enrichment analysis of module 2. (G) Go enrichment analysis of module 3. (H) KEGG pathway enrichment analysis of module 3.
FIGURE 6(A) Molecular docking of four compounds with EGFR. (B) Molecular docking of caffeic acid with EGFR. (C) Molecular docking of danshensu with EGFR docking diagram. (D) Molecular docking of ferulic acid with EGFR. (E) Molecular docking of rosmarinic acid with EGFR.
Basic information of docking results of 10 key targets with related compounds.
| Target | PDB ID | Compound | Affinity (kcal/mol) |
|---|---|---|---|
| APP | 1AAP | Caffeic acid | −6.8 |
| Ferulic acid | −6.0 | ||
| Rosmarinic acid | −7.4 | ||
| Salvianolic acid B | −8.8 | ||
| EGFR | 3W2S | Caffeic acid | −7.3 |
| Danshensu | −6.6 | ||
| Ferulic acid | −7.0 | ||
| Rosmarinic acid | −9.5 | ||
| JUN | 1JNM | Salvianolic acid B | −6.4 |
| MAPK1 | 5WP1 | Caffeic acid | −6.6 |
| Cytidine | −6.3 | ||
| Ferulic acid | −6.6 | ||
| MAPK3 | 4QTB | Ferulic acid | −6.9 |
| MAPK8 | 3PZE | Rosmarinic acid | −7.6 |
| PIK3CA | 3HHM | Caffeic acid | −7.0 |
| SRC | 1Y57 | Salvianolic acid A | −8.1 |
| STAT3 | 6NJS | Caffeic acid | −5.8 |
| Ferulic acid | −5.9 | ||
| Salvianolic acid A | −7.5 | ||
| TNF | 1TNF | Rosmarinic acid | −9.3 |
FIGURE 7(A) DHI-key compound-key target-pathway network. The blue diamond represents DHI; Cyan V-type represents the key compound; the light blue circle represents the key target; the purple hexagon represents the pathways enriched by key targets; the red hexagon represents the calcium signaling pathway. (B) Schematic diagram of the calcium signaling pathway (hsa04020).
FIGURE 8(A) The effect of DHI on ejection fraction and left ventricular short axis shortening rate in AMI model rats ( ±s). **p < 0.01 vs. sham; △△ p < 0.01 vs. model. (B) The effect of DHI on end-diastolic and end-systolic ventricular intimal thickness of AMI model rats ( ±s). **p < 0.01 vs. sham; △△ p < 0.01 vs. model. (C) The effect of DHI on cardiac function in rats with AMI. a: sham group; b: model group; c: DHI 6 mg/kg group. (D) The effect of DHI on myocardial infarction size in AMI model rats. a: sham group; b: model group; c: DHI 6 mg/kg group. (E) The effect of DHI on myocardial infarction size in AMI model rats ( ±s). **p < 0.01 vs. sham; △△ p < 0.01 vs. model.
The effect of DHI on ejection fraction and left ventricular short axis shortening rate in acute myocardial infarction model rats ( ±s).
| LViD |
| EF (%) | FS (%) |
|---|---|---|---|
| Group | |||
| Sham group | 17 | 79.68 ± 7.25 | 50.00 ± 7.24 |
| Model group | 17 | 36.10 ± 11.70 | 18.17 ± 6.42 |
| DHI 6 ml/kg group | 24 | 62.54 ± 20.90 | 37.35 ± 17.29 |
p < 0.01 vs. sham.
p < 0.01 vs. model; LViD, left ventricular internal diameter.
The effect of DHI on end-diastolic and end-systolic ventricular intimal thickness of acute myocardial infarction model rats ( ±s).
| IT |
| LVAW d (mm) | LVAW s (mm) |
|---|---|---|---|
| Group | |||
| Sham group | 17 | 1.80 ± 0.31 | 2.94 ± 0.43 |
| Model group | 17 | 1.49 ± 0.25 | 1.51 ± 0.28 |
| DHI 6 ml/kg group | 24 | 1.65 ± 0.39 | 2.23 ± 0.74 |
p < 0.01 vs. sham.
p < 0.01 vs. model; IT, intimal thickness.
The effect of DHI on myocardial infarction size in acute myocardial infarction model rats ( ±s).
| Group |
| A/B (%) | A/C (%) |
|---|---|---|---|
| Sham group | 11 | 0.26 ± 0.26 | 0.17 ± 0.18 |
| Model group | 12 | 23.21 ± 6.14 | 14.97 ± 4.46 |
| DHI 6 ml/kg group | 20 | 11.21 ± 4.06 | 7.43 ± 2.56 |
A, myocardial infarction size; B, ventricular size; C, total heart size.
p < 0.01 vs. sham.
p < 0.01 vs. model.
FIGURE 9(A) The effect of DHI on AMI model rats (HE staining). a: sham group; b: model group; c: DHI 6 mg/kg group. (B) The effect of DHI on AMI model rats (Masson staining). a: sham group; b: model group; c: DHI 6 mg/kg group. (C) Effect of DHI on the expression of PLB protein in the myocardium of AMI model rats (n = 3, ±s). **p < 0.01 vs. sham; △△ p < 0.01 vs. model. (D) Effect of DHI on the expression of CaMK II protein in the myocardium of rats with AMI (n = 4, ±s). **p < 0.01 vs. sham; △△ p < 0.01 vs. model. (E) Effect of DHI on the expression of SERCA protein in the myocardium of rats with AMI (n = 4, ±s). **p < 0.01 vs. sham; △△ p < 0.01 vs. model. 14 Table legends.
Effect of DHI on myocardial protein expression in rats with AMI ( ±s).
| Group | PLB ( | CaMK II ( | SERCA ( |
|---|---|---|---|
| Sham group | 1.64 ± 0.09 | 0.43 ± 0.05 | 0.71 ± 0.07 |
| Model group | 1.98 ± 0.16 | 0.73 ± 0.03 | 0.41 ± 0.06 |
| DHI 6 ml/kg group | 1.78 ± 0.21 | 0.50 ± 0.05 | 0.76 ± 0.12 |
p < 0.01 vs. sham.
p < 0.01 vs. model.